Exelixis FDA extends NDA review for zanzalintinib
The FDA extended review of Exelixis's NDA for zanzalintinib plus atezolizumab by three months, setting a new PDUFA date of March 3, 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.